BREAKING NEWS
This content is not available in your region

U.S. FDA approves AstraZeneca's diabetes drug for treating heart failure risk

Access to the comments Comments
U.S. FDA approves AstraZeneca's diabetes drug for treating heart failure risk
FILE PHOTO: A man walks past a sign at an AstraZeneca site in Macclesfield, England May 19, 2014. REUTERS/Phil Noble/File Photo   -   Copyright  Phil Noble(Reuters)
Text size Aa Aa

(Reuters) – AstraZeneca Plc <AZN.L> said on Monday U.S. regulators approved its diabetes drug Farxiga to be used as a treatment to reduce the chances of hospitalisation for heart failure in adults with type-2 diabetes and other cardiovascular risks.

The approval by the U.S. Food and Drug Administration is based on results from the DECLARE-TIMI 58 clinical trial, the British drugmaker said and follows a similar approval https://www.astrazeneca.com/media-centre/press-releases/2019/forxiga-label-updated-in-the-eu-in-type-2-diabetes.html by the European authorities in August.

Diabetes is associated with a high risk of heart failure.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on euronews.com for a limited time.